Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $962000.0.

  • Tonix Pharmaceuticals Holding's Capital Expenditures rose 1058888.89% to $962000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 16990.99%. This contributed to the annual value of $120000.0 for FY2024, which is 9848.01% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Capital Expenditures of $962000.0 as of Q3 2025, which was up 1058888.89% from $527000.0 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Capital Expenditures' 5-year high stood at $3.8 million during Q1 2023, with a 5-year trough of $3000.0 in Q4 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Capital Expenditures averaged around $951000.0, with its median value being $482500.0 (2023).
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Capital Expenditures crashed by 9950.36% in 2024, and later skyrocketed by 1058888.89% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Capital Expenditures (Quarter) stood at $438000.0 in 2023, then tumbled by 99.32% to $3000.0 in 2024, then surged by 31966.67% to $962000.0 in 2025.
  • Its Capital Expenditures was $962000.0 in Q3 2025, compared to $527000.0 in Q2 2025 and $6000.0 in Q1 2025.